Safety and Efficacy of Clobetasol Propionate 0.05% E Foam in Alopecia

• Status: Unknown status
• Trial end date: 2010-10-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to ascertain the safety and efficacy of

Clobetasol Propionate 0.05% E Foam in the treatment of Central Centrifugal

Cicatricial Alopecia.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Callender Center for Clinical Research
• Treatments: Clobetasol; Emollients

Criteria

Inclusion Criteria:

• Patients with CCCA, treated or untreated

• Score 0 - 1 on Scale/Questionnaire

• 18 years of age or older

• Women of African descent

Exclusion Criteria:

• Score > 1 on Scale/Questionnaire

• Alopecias other than CCCA, including alopecia arreata, lichen planopilaris, trichotillomania, and traction alopecia

• History of hair transplantation

• Children less than 18 years of age

• Males

• Women of non-African descent

• Pregnancy or breastfeeding. Women of childbearing age must use reliable forms of contraception (e.g., abstinence, oral contraceptives, or spermicide and condoms)

• Anti-dandruff shampoo within 30 days

• Anti-inflammatory medications such as antibiotics (doxycycline, minocycline, rifampin, etc.), steroids (oral prednisone, topical corticosteroids,etc.), NSAIDs (ibuprofen, aspirin, etc.)